Related Experiment Video

Updated: Apr 5, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.5K

[CORONARY ARTERY DISEASE AND HEART FAILURE: A GENOTYPE-BASED THERAPEUTIC APPROACH]

P Lancellotti, A Ancion

    Revue Medicale De Liege
    |August 20, 2015
    PubMed

    Insights

    Genetic variations can affect how well treatments work for heart conditions like coronary artery disease and heart failure. Genotype-guided therapy offers personalized medicine for improved treatment efficacy and patient safety.

    Area of Science:

    • Cardiovascular Medicine
    • Pharmacogenomics
    • Genetics

    Context:

    • Prospective randomized trials in coronary artery disease (CAD) and heart failure (HF) have improved patient prognosis using phenotypic treatment approaches.
    • However, individual genetic variations (polymorphisms) can influence the efficacy of common cardiovascular medications.

    Purpose:

    • To explore the impact of gene polymorphisms on the effectiveness of anti-platelet drugs, beta-blockers, and ACE-inhibitors in patients with CAD and HF.
    • To highlight the potential of genotype-guided therapeutic strategies for personalized cardiovascular medicine.

    Summary:

    • Gene polymorphisms significantly affect patient response to standard treatments for coronary artery disease and heart failure.
    • Medications such as anti-platelets, beta-blockers, and angiotensin-converting enzyme (ACE) inhibitors show variable efficacy based on an individual's genetic makeup.
    • Genotype-based treatment selection is emerging as a key strategy to optimize therapeutic outcomes.

    Impact:

    • Personalized medicine approaches based on genetic profiles can enhance treatment efficacy in cardiovascular diseases.
    • Tailoring therapies according to genotype may lead to improved patient safety and reduced adverse events.
    • This pharmacogenomic approach promises to revolutionize the management of coronary artery disease and heart failure.

    More Related Videos

    Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart06:07

    Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

    Published on: September 2, 2021

    2.3K
    A Modified Technique for Transverse Aortic Constriction in Mice04:52

    A Modified Technique for Transverse Aortic Constriction in Mice

    Published on: August 18, 2022

    6.1K

    Related Concept Videos

    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
    86
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    546
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    1.4K
    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    114
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    69
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    1.4K